Evaluating the coding accuracy of type 2 diabetes mellitus among patients with non-alcoholic fatty liver disease

被引:0
作者
Lee, Seungwon [1 ,2 ,3 ,4 ]
Shaheen, Abdel Aziz [1 ,2 ,5 ]
Campbell, David J. T. [1 ,5 ,7 ]
Naugler, Christopher [1 ,6 ]
Jiang, Jason [2 ,3 ]
Walker, Robin L. [1 ,2 ]
Quan, Hude [1 ,2 ]
Lee, Joon [1 ,2 ,4 ,7 ]
机构
[1] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB T2N 4Z6, Canada
[2] Univ Calgary, Ctr Hlth Informat, Cumming Sch Med, Calgary, AB, Canada
[3] Alberta Hlth Serv, Calgary, AB, Canada
[4] Univ Calgary, Cumming Sch Med, Data Intelligence Hlth Lab, Calgary, AB, Canada
[5] Univ Calgary, Cumming Sch Med, Dept Med, Calgary, AB, Canada
[6] Univ Calgary, Cumming Sch Med, Dept Pathol & Lab Med, Calgary, AB, Canada
[7] Univ Calgary, Cumming Sch Med, Dept Cardiac Sci, Calgary, AB, Canada
基金
加拿大健康研究院;
关键词
Diabetes mellitus; International classification of diseases; Non-alcoholic fatty liver disease; Routinely collected health data; Health services research; COMORBIDITY INDEX; PREVALENCE;
D O I
10.1186/s12913-024-10634-8
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BackgroundNon-alcoholic fatty liver disease (NAFLD) describes a spectrum of chronic fattening of liver that can lead to fibrosis and cirrhosis. Diabetes has been identified as a major comorbidity that contributes to NAFLD progression. Health systems around the world make use of administrative data to conduct population-based prevalence studies. To that end, we sought to assess the accuracy of diabetes International Classification of Diseases (ICD) coding in administrative databases among a cohort of confirmed NAFLD patients in Calgary, Alberta, Canada.MethodsThe Calgary NAFLD Pathway Database was linked to the following databases: Physician Claims, Discharge Abstract Database, National Ambulatory Care Reporting System, Pharmaceutical Information Network database, Laboratory, and Electronic Medical Records. Hemoglobin A1c and diabetes medication details were used to classify diabetes groups into absent, prediabetes, meeting glycemic targets, and not meeting glycemic targets. The performance of ICD codes among these groups was compared to this standard. Within each group, the total numbers of true positives, false positives, false negatives, and true negatives were calculated. Descriptive statistics and bivariate analysis were conducted on identified covariates, including demographics and types of interacted physicians.ResultsA total of 12,012 NAFLD patients were registered through the Calgary NAFLD Pathway Database and 100% were successfully linked to the administrative databases. Overall, diabetes coding showed a sensitivity of 0.81 and a positive predictive value of 0.87. False negative rates in the absent and not meeting glycemic control groups were 4.5% and 6.4%, respectively, whereas the meeting glycemic control group had a 42.2% coding error. Visits to primary and outpatient services were associated with most encounters.ConclusionDiabetes ICD coding in administrative databases can accurately detect true diabetic cases. However, patients with diabetes who meets glycemic control targets are less likely to be coded in administrative databases. A detailed understanding of the clinical context will require additional data linkage from primary care settings.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease
    Tada, Toshifumi
    Toyoda, Hidenori
    Sone, Yasuhiro
    Yasuda, Satoshi
    Miyake, Nozomi
    Kumada, Takashi
    Tanaka, Junko
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (11) : 2011 - 2018
  • [42] Association of leukocyte telomere length with non-alcoholic fatty liver disease in patients with type 2 diabetes
    Zhang, Min
    Hu, Man-Li
    Huang, Jiao-Jiao
    Xia, San-Shan
    Yang, Yan
    Dong, Kun
    CHINESE MEDICAL JOURNAL, 2019, 132 (24) : 2927 - 2933
  • [43] Non-alcoholic fatty liver disease and type 2 diabetes mellitus: general approaches to the choice of therapy
    Petunina, Nina A.
    Telnova, Milena E.
    Goncharova, Ekaterina V.
    Martirosian, Narine S.
    Kuzina, Irina A.
    TERAPEVTICHESKII ARKHIV, 2022, 94 (10) : 1155 - 1162
  • [44] The Effect of Semaglutide on Glycolipid Metabolism in Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
    Ding, Li Ping
    Liu, Shen Kun
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 84 : 171 - 175
  • [45] Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus
    Wei-Dong Li
    Kun-Fa Fu
    Gui-Mei Li
    Yan-Shu Lian
    Ai-Min Ren
    Yun-Jue Chen
    Jin-Rong Xia
    World Journal of Gastroenterology, 2015, (32) : 9607 - 9613
  • [46] Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
    Tian, Feng
    Zheng, Zhigang
    Zhang, Damin
    He, Si
    Shen, Jie
    BIOSCIENCE REPORTS, 2018, 38
  • [47] Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes
    Seo, D. H.
    Lee, Y-H
    Park, S. W.
    Choi, Y. J.
    Huh, B. W.
    Lee, E.
    Huh, K. B.
    Kim, S. H.
    Cha, B-S
    DIABETES & METABOLISM, 2020, 46 (05) : 362 - 369
  • [48] Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes
    Afarideh, Mohsen
    Aryan, Zahra
    Ghajar, Alireza
    Ganji, Morsaleh
    Ghaemi, Fatemeh
    Saadatagah, Seyedmohammad
    Heidari, Behnam
    Mechanick, Jeffrey
    Esteghamati, Alireza
    PRIMARY CARE DIABETES, 2019, 13 (06) : 505 - 514
  • [49] Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
    Fan, Hui
    Pan, QingRong
    Xu, Yuan
    Yang, XinChun
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2013, 57 (09) : 702 - 708
  • [50] Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes
    Bayliss, Jacqueline
    Ooi, Geraldine J.
    De Nardo, William
    Shah, Yazmin Johari Halim
    Montgomery, Magdalene K.
    McLean, Catriona
    Kemp, William
    Roberts, Stuart K.
    Brown, Wendy A.
    Burton, Paul R.
    Watt, Matthew J.
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12